



# Understanding Digital Therapeutics and the Regulatory Landscape

**Disease State Education** 

© 2024 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD

April 2024 US.PSY.D.24.00010



#### This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)







If you or someone you know is in crisis, call: **Suicide Prevention** Hotline/Lifeline 1-800-273-TALK(8255) Or text: **Crisis Text Line** 741-741 **Dial 988** 





### Objectives

#### Distinguish the Different Digital Tools

Compare Benefits and Barriers of Digital Therapeutics Review the US Regulatory and Reimbursement Pathways for Digital Therapeutics





### **Digital Therapeutics Overview**



### **Understanding Digital Therapeutics**


# DTx deliver **SOFTWARE-BASED INTERVENTIONS** to patients to **TREAT and ALLEVIATE** a disease or condition<sup>3</sup>



DTx are supported by clinical data and should be guided by real-world evidence<sup>1</sup>



Some DTx can be used independently, while others are used alongside medications or other devices or therapies<sup>1</sup>



DTx may **increase access** to clinically validated therapies that may **improve patient outcomes**<sup>2</sup>


DTx, digital therapeutics.

- 1. Digital Therapeutics Alliance. November 2019. Accessed February 7, 2023. https://dtxalliance.org/wp-content/uploads/2021/01/DTA\_DTx-Definition-and-Core-Principles.pdf.
- 2. Digital Therapeutics Alliance. Accessed March 6, 2023. https://dtxalliance.org/.
- 3. Digital Therapeutics Alliance. June 2023. Accessed October 9, 2023. https://dtxalliance.org/wp-content/uploads/2023/06/Guidance-to-Industry-Classification-of-Digital-Health-Technologies-2023Jun05.pdf



### Distinguishing Between Digital Mental Health Tools

Digital mental health tools are technologies that use computing platforms, connectivity, software, and sensors for mental health care.<sup>1</sup> These tools can be categorized, among other things, as a health and wellness app, a patient monitoring and assessment tool, or a digital therapeutic.<sup>2</sup>



Digital Therapeutics Alliance. June 2023. Accessed October 9, 2023. https://dtxalliance.org/wp-content/uploads/2023/06/Guidance-to-Industry-Classification-of-Digital-Health-Technologies-2023Jun05.pdf



### Identifying DTx in Mental Health Care

#### Is this a digital therapeutic?<sup>1,2</sup>




AI, artificial intelligence; DTx, digital therapeutics.

- 1. Digital Therapeutics Alliance. June 2022. Accessed February 7, 2023. https://dtxalliance.org/wp-content/uploads/2022/09/DTA\_FS\_Is-This-Product-a-DTx.pdf.
- 2. Goldsack J, et al. November 10, 2019. Accessed February 7, 2023. https://www.dimesociety.org/digital-health-digital-medicine-digital-therapeutics-dtx-whats-the-difference/.



#### DTx May Be Accessed in Different Ways



Some DTx are provided as an **employer or health plan benefit** 

DTx, digital therapeutic(s); HCP, healthcare professional.


1. Digital Therapeutics Alliance. September 2022. Accessed April 10, 2023. https://dtxalliance.org/understanding-dtx/what-is-a-dtx/.





### Benefits and Barriers of Digital Therapeutics





cover certain DTx, but coverage remains a care and empower them in selfchallenge<sup>4</sup>

#### In countries with state-run healthcare systems, DTx are increasingly being assessed to make them available to patients<sup>5,6</sup>

#### DTx, digital therapeutics.

- Duerr HA. Psychiatr Times. 2022;39(10):14-15.
- 2. Whitelaw S, et al. Eur Heart J Digit Health. 2021;2(1):62-74.
- Appold K. August 17, 2021. Accessed February 27, 2023. https://www.enttoday.org/article/closing-3. the-digital-divide-ensuring-patients-have-access-to-healthcare-technology-is-a-priority.

management

- Lovett L. October 26, 2022. Accessed February 17, 2023. https://bhbusiness.com/2022/10/26/clarity-4. on-digital-therapeutics-reimbursement-could-lead-to-more-behavioral-health-adoption/.
- 5 Digital Therapeutics Alliance, June 2021, Accessed March 20, 2023, https://dtxalliance.org/wpcontent/uploads/2021/06/DTA\_DTx-Overview\_UK.pdf.
- GlobalData Healthcare. January 22, 2021. Accessed March 20, 2023. https://www.pharmaceutical-6. technology.com/comment/digital-therapeutics-germany/



### Benefits and Barriers of DTx for HCPs

#### **BENEFITS**<sup>1</sup>

#### BARRIERS

- May directly impact disease state measures and patients' clinical outcomes
- May expand HCPs' ability to provide safe and effective treatment by:
  - Providing therapies for previously untreated or undertreated conditions
  - Extending their ability to care for patients
  - Closing gaps in care between appointments
- May help optimize HCP-patient engagement

- HCPs may<sup>2,3</sup>:
  - Lack awareness of and knowledge about DTx
  - Feel that DTx are not comparable to traditional treatments
  - Fear that DTx will create more work and responsibility for themselves
  - Fear that DTx will increase patient burden
  - Experience technology challenges
  - Hesitate to use DTx if they do not integrate with EHRs or have customizable features
  - Have data privacy and security concerns
  - Have concerns about reimbursement

DTx, digital therapeutics; EHR, electronic health record; HCP, healthcare professional.

- 1. Digital Therapeutics Alliance. Accessed February 27, 2023. https://dtxalliance.org/value-of-dtx/clinicians/.
- 2. Secker-Johnson R, et al. February 2, 2022. Accessed February 27, 2023. https://www.zs.com/insights/barriers-to-broad-dtx-adoption-and-ways-to-overcome.
- Whitelaw S, et al. *Eur Heart J Digit Health*. 2021;2(1):62-74.





### Benefits and Barriers of DTx for Payers

#### **BENEFITS**<sup>1</sup>

#### DTx may help:

- Enhance, support, and optimize current medical treatments
- Reduce the overall cost of care
- Improve provider network efficiency
- Support value- and outcomes-based care initiatives
- Expand care delivery outside of traditional clinic settings
- Improve member experience and satisfaction

#### **BARRIERS**<sup>2</sup>

#### Payers may:

- Lack familiarity with DTx
- Be uncomfortable with the regulatory process since DTx are typically reviewed as medical devices
- Desire more clinical evidence
- Be unwilling to pay for "convenience"
- Believe there is a lack of clinical value
- Believe that DTx are a low priority for patients and HCPs

DTx, digital therapeutics; HCP, healthcare professional.

- 1. Digital Therapeutics Alliance. Accessed February 27, 2023. https://dtxalliance.org/value-of-dtx/payors/.
- 2. Melillo G. May10, 2022. Accessed February 27, 2023. https://www.ajmc.com/view/what-s-behind-lagging-payer-uptake-of-prescription-digital-therapeutics-.







### **Regulatory and Reimbursement Pathways**



### Regulatory Pathways in the United States

#### IN THE US, DTx ARE SUBJECT TO REGULATION AS MEDICAL DEVICES BY THE FDA<sup>1</sup>

The FDA categorizes medical devices into 3 classes based on their risk and required level of regulatory control<sup>1-4</sup>:

	CLASS I	CLASS II	CLASS III	To increase access to care during the COVID-
Level of risk	Low risk	Moderate risk	High risk	19 public health emergency, the FDA allowed digital psychiatric health devices to be marketed prior to obtaining regulatory clearance <sup>5</sup> This enforcement discretion expired in 2023 <sup>6</sup>
Most likely pathway to regulatory clearance	None—most Class I devices are exempt from regulatory review	<b>510(k) pathway</b> Demonstrates that the device is substantially equivalent <sup>a</sup> to a legally marketed predicate device	<b>PMA pathway</b> Like an NDA, a PMA is the required process of scientific review to ensure the safety and effectiveness of devices	

6.

<sup>a</sup>A substantially equivalent device has (a) the same intended use as the predicate and (b) the same technological characteristics *or* different technological characteristics but does not raise different questions of safety and effectiveness. This information submitted to the FDA demonstrates that the device is as safe and effective as the legally marketed predicate device.<sup>2</sup> FDA, US Food & Drug Administration; NDA, New Drug Application; PMA; Premarket Approval Application. 5.

- 1. US Food & Drug Administration. December 19, 2017. Accessed February 17, 2023. https://www.fda.gov/about-fda/cdrh-transparency/overview-medical-device-classification-and-reclassification.
- US Food & Drug Administration. October 3, 2022. Accessed February 17, 2023. https://www.fda.gov/medicaldevices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k.

US Food & Drug Administration. December 16, 2021. Accessed February 17, 2023. https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/pma-approvals.

Digital Therapeutics Alliance. Accessed February 19, 2023. https://dtxalliance.org/wp-content/uploads/2022/01/US-Regulatory-and-Reimbursement-Pathways.pdf.

- US Food & Drug Administration. April 2020. Accessed February 17, 2023. https://www.fda.gov/media/136939/download.
- US Department of Health & Human Services. Accessed February 17, 2023. https://www.fda.gov/media/136939/download.



### Reimbursement Pathways in the United States

#### **GOVERNMENT-SPONSORED HEALTH INSURANCE**

- **DTx generally are not covered** by government-sponsored health insurance, but steps are being taken to address this
  - The Access to Prescription Digital Therapeutics Act of 2023, originally introduced in the US Senate in March 2022 and updated in March 2023, aims to amend the Social Security Act to provide Medicare coverage for PDT<sup>1,2</sup>
  - The Medicaid and CHIP Access to Prescription Digital Therapeutics Act, introduced in the US Senate in December 2022, would require CMS to provide guidance on coverage for DTx under Medicaid and the State Children's Health Insurance Program<sup>3</sup>
  - Some state Medicaid programs have announced partnerships to cover certain DTx<sup>4</sup>

COMMERCIAL HEALTH INSURANCE	US DEPARTMENT OF VETERANS AFFAIRS	
<ul> <li>Commercial insurance plans are starting to cover certain DTx, but coverage remains a challenge<sup>4</sup></li> </ul>	<ul> <li>Some DTx are covered by the Veterans Benefits Administration<sup>5,6</sup></li> </ul>	
HIP, Children's Health Insurance Program; CMS, Centers for Medicare & Medicaid Services; DTx, digital therapeutics; DT, prescription digital therapeutics.	<ol> <li>Lovett L. October 26, 2022. Accessed February 17, 2023. https://bhbusiness.com/2022/10/26/clarity-on-digital- therapeutics-reimbursement-could-lead-to-more-behavioral-health-adoption/.</li> </ol>	
US Congress. March 10, 2022. Accessed February 17, 2023. https://www.congress.gov/bill/117th-congress/senate- bill/3791/text.	<ol> <li>Freespira. Accessed February 10, 2023. https://freespira.com/.</li> <li>Military.com. Accessed March 27, 2023. https://www.military.com/military-life/smartwatch-app-ptsd-related-</li> </ol>	
. AMCP. March 9, 2023. Accessed March 20, 2023. https://www.amcp.org/About/Media/Press-Releases/amcp- applauds-access-prescription-digital-therapeutics-act	nightmares-now-available-prescription-va-dod.html.	
US Congress. December 12, 2022. Accessed February 17, 2023. https://www.congress.gov/bill/117th- congress/senate-bill/5238/text.		



### For more information or to request a more detailed live presentation on this topic from your local Medical Science Liaison, please visit www.PsychU.org/events

# www.PsychU.org



### Get Your Resources On The Go



Download the **PsychU** App from Google Play or from the Apple App Store!



app.

Subscribe to The PsychU Community Podcast on the Google Podcasts app or on the Apple Podcasts

# Connect with us on social media:



